Cargando…

Can a rational design for metronomic chemotherapy dosing be devised?

Detalles Bibliográficos
Autores principales:	Maraveyas, A, Lam, T, Hetherington, J W, Greenman, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362004/ https://www.ncbi.nlm.nih.gov/pubmed/15846302 http://dx.doi.org/10.1038/sj.bjc.6602474

Ejemplares similares

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)

Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract
por: Liu, Hailing, et al.
Publicado: (2023)

Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients
por: Jung, Yun Hwa, et al.
Publicado: (2017)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

The need to devise government-spearheaded measures to prevent loneliness and isolation in conjunction with the spread of COVID-19 in Japan
por: Inoue, K., et al.
Publicado: (2021)

Metronomic Chemotherapy in Prostate Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2022)

Fixed-dose combinations: An essential for rational preparation
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2021)

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2017)

Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy
por: Sales, María E., et al.
Publicado: (2019)

Low‐dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma
por: Chen, Yu‐Pei, et al.
Publicado: (2022)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
por: KIBATA, KAYOKO, et al.
Publicado: (2013)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

The European Prescribing Exam: assessing whether European medical students can prescribe rationally and safely
por: Donker, Erik M., et al.
Publicado: (2022)

Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
por: Koltai, Tomas, et al.
Publicado: (2019)

Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer patients during COVID-19 Pandemic
por: Imaduddin, Mohammed, et al.
Publicado: (2021)

Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas
por: Sheng Sow, Heng, et al.
Publicado: (2013)

Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial
por: Hart, C., et al.
Publicado: (2015)

Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O.G., et al.
Publicado: (2009)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

Metronomic palliative chemotherapy in maxillary sinus tumor
por: Patil, Vijay M., et al.
Publicado: (2016)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Rational design and crystallographic analysis of novel isoform-selective TRKA inhibitors for cancer therapy
por: Wang, Guan, et al.
Publicado: (2023)

Devise Plans for Regulating Practice of Medicine
Publicado: (1908)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
por: Isono-Nakata, Rose, et al.
Publicado: (2018)

Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
por: Schito, Luana, et al.
Publicado: (2020)

Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
por: Krajnak, S., et al.
Publicado: (2020)

Reducing moral distress associated with rationing of healthcare resources
por: Breiburg, A., et al.
Publicado: (2021)

Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2021)

Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy
por: Shamash, J, et al.
Publicado: (2000)

Snakebite management in Iran: Devising a protocol
por: Monzavi, Seyed Mostafa, et al.
Publicado: (2014)

Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”
por: Kepka, Lucyna, et al.
Publicado: (2021)

Devising Mobile Sensing and Actuation Infrastructure with Drones
por: Bae, Mungyu, et al.
Publicado: (2018)

Demonstration of the Recently Devised Pancreatic Reaction in the Urine
por: Watson, Chalmers
Publicado: (1908)

Use of metronomic chemotherapy in the management of a cat with abdominal haemangiosarcoma
por: Yee-Ka Cheng, Katrina, et al.
Publicado: (2018)

Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
por: Simsek, Cem, et al.
Publicado: (2019)

Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review
por: Parshad, Shruti, et al.
Publicado: (2022)

Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy
por: Andres, R, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_8t8prbpmj16od4qtmisubki05r